Marksans Pharma Ltd.
NSE: MARKSANS · Healthcare
Sector
Healthcare
Size band
Small cap
Market cap
7,704cr
P/E
31.3
ROE
14.4%
Dividend yield
0.5%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Marksans Pharma Ltd. | 25.0% | 35.6% |
What management said
8 statements on recordEarnings call · Q1 FY27 · 20 Aug 2026
- FY27 revenue growth and EBITDA margin→15% to 20% revenue growth; 20% to 21% EBITDA margin· FY27
“Meet Bhuva: Yeah, hi, sir. Congratulations on a great set of numbers first of all. And I have a couple of questions. So, we have clocked around 25% on the bottom-line in quarter one. So like -- and also, we have guided for FY27 revenue growth of 15% to 20% and 20% to 21% EBITDA margin. So, is there any plan to revise based on the upward side, or how should we look at it? Mark Saldanha: No, I think we'll stick with that plan because of the volatility that you see, the geopolitical scenarios that you see prevailing, surrounding us and pretty much all countries.”
- QliniQ revenue→around INR150 crores to INR175 crores· FY27
“We expect QliniQ will do around INR150 crores to INR175 crores in terms of the revenue overall for the year.”
- Europe revenue→INR180 crores· FY27
“We expect to end this year by around about -- between EUR14 million to EUR15 million, that's really about 40% above. So we do expect Europe to be somewhere around INR180 crores to -- yes, about INR180 crores. You can put it at INR180 crores.”
- Gross margin→55%, 56% gross margin
“And yes, in terms of sustainability of that 25-odd percent -- yes, 59%, I think we should be around 55%, 56% gross margin per se.”
- Revenue→INR4,000 crores· within the next two years
“We do anticipate us -- I mean, we are still very much on our target of hitting INR4,000 crores within the next two years. So I think we still stand by it.”
- EBITDA margin→21% to 22%· end of the year
“Abhi Jain: By the end of the year 21% to 22 percentage? Mark Saldanha: Yes. End of the year, 21% to 22% is achievable. Yes.”
- U.S. revenue→$300 million
“So obviously our immediate outlook, you know, we don't talk about $200 million anymore, but we are now working towards a $300 million and then we'll probably look at a $400 million, if you have to look at a horizon of maybe five years. But I think our immediate objective is to first reach our next benchmark of $300 million in the U.S.”
- Revenue→doubling our revenue· within the next five years
“So I mean, it is -- we still have to work towards that and we are quite optimistic we will be out there.”
Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.
On air
20 calls · outcomes not trackedRecorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.
| Channel & show | Aired | Stated target | Stated stop | Outcome |
|---|---|---|---|---|
| NDTV ProfitNDTV Profit · no registration attached | 24 Sep | +8.8% | -4.1% | still open |
| NDTV ProfitNDTV Profit · no registration attached | 24 Sep | +8.2% | -4.7% | still open |
| NDTV ProfitNDTV Profit · no registration attached | 24 Sep | +7.9% | -5.0% | still open |
| NDTV ProfitNDTV Profit · no registration attached | 24 Sep | +7.8% | -6.7% | still open |
| NDTV ProfitNDTV Profit · no registration attached | 24 Sep | +7.6% | -5.2% | still open |
| NDTV ProfitNDTV Profit · no registration attached | 24 Sep | +7.2% | -5.5% | still open |
| Zee BusinessZee Business · no registration attached | 24 Sep | +4.3% | -2.0% | still open |
| Zee BusinessZee Business · no registration attached | 24 Sep | +2.6% | -2.0% | still open |
| NDTV ProfitNDTV Profit · no registration attached | 24 Sep | +6.6% | -6.1% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 22 Sep | +2.7% | -5.6% | still open |
| Zee BusinessZee Business · no registration attached | 22 Sep | +4.4% | -1.8% | still open |
| Zee BusinessZee Business · no registration attached | 22 Sep | +2.1% | -1.8% | still open |
| Zee BusinessZee Business · no registration attached | 22 Sep | +4.4% | — | still open |
| Zee BusinessZee Business · no registration attached | 22 Sep | +2.1% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 21 Sep | +5.1% | -3.3% | still open |
| Zee BusinessZee Business · no registration attached | 13 Aug | +5.8% | -8.7% | still open |
| Zee BusinessZee Business · no registration attached | 13 Aug | +12.2% | — | still open |
| Zee BusinessZee Business · no registration attached | 13 Aug | +8.2% | -6.6% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 13 Aug | — | -10.4% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 12 Aug | — | -10.4% | still open |
Shareholding
change across 4 filings| Category | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Change |
|---|---|---|---|---|---|
| Promoters | 43.9 | 43.9 | 43.9 | 43.9 | 0.0 |
| Foreign institutions | 19.1 | 17.5 | 16.8 | 16.7 | +2.4 |
| Domestic institutions | 5.5 | 6.2 | 6.6 | 5.9 | −0.4 |
| Retail & others | 31.5 | 32.5 | 32.8 | 33.5 | −2.0 |
As filed with the exchange for the periods ending Dec 25 to Sep 26.
Filings
latest 25 of 244- Certificate under SEBI (Depositories and Participants) Regulations, 201813 Oct 2026
- Trading Window25 Sept 2026
- General Updates17 Sept 2026
- Notice to Shareholders regarding re-opening of Special Window for Re-lodgement of transfer requests of Physical Shares17 Sept 2026
- Copy of Newspaper Publication7 Sept 2026
- Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF7 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates1 Sept 2026
- Intimation of schedule of Investors Meet1 Sept 2026
- Please find attached the voting result of the 34th AGM27 Aug 2026
- Shareholders meeting27 Aug 2026
- Scrutinizer''s Report along with voting result for the 34th AGM27 Aug 2026
- Shareholders meeting27 Aug 2026
- Proceeding of 34th Annual General Meeting of the Company held today27 Aug 2026
- General Updates26 Aug 2026
- Please find attached disclosure on ESG rating26 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates20 Aug 2026
- Transcript of Investors/Analyst meet on Q1 FY 27 Financial Results20 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates13 Aug 2026
- Copy of Newspaper Publication13 Aug 2026
- Press Release12 Aug 2026
- Investor Presentation12 Aug 2026
- Outcome of Board Meeting12 Aug 2026
- Copy of Newspaper Publication6 Aug 2026
- Updates4 Aug 2026
- Shareholders meeting4 Aug 2026
The 25 most recent of 244 filings we hold for MARKSANS, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.